Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 2 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose - treatment of hypertension. treatment of heart failure. in such patients it is recommended that perindopril be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril have not been demonstrated for new york heart association category iv patients). patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of nonfatal myocardial infarction or cardiac arrest.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose - treatment of hypertension. treatment should not be initiated with this combination.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 5 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; maltodextrin; sodium starch glycollate type a; colloidal anhydrous silica; lactose monohydrate; colour - treatment of hypertension. treatment should not be initiated with this combination.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg; indapamide hemihydrate, quantity: 0.625 mg - tablet, film coated - excipient ingredients: macrogol 6000; colloidal anhydrous silica; lactose monohydrate; maltodextrin; magnesium stearate; sodium starch glycollate type a; colour - treatment of hypertension.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; sodium bicarbonate; lactose monohydrate; iron oxide red; purified talc; magnesium stearate - indications: hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril sandoz be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - trandolapril, quantity: 4 mg; verapamil hydrochloride, quantity: 240 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; povidone; hypromellose; sodium stearylfumarate; microcrystalline cellulose; sodium alginate; magnesium stearate; hyprolose; macrogol 400; macrogol 6000; purified talc; colloidal anhydrous silica; titanium dioxide; iron oxide red; iron oxide yellow; iron oxide black; docusate sodium - tarka is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - trandolapril, quantity: 2 mg; verapamil hydrochloride, quantity: 180 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; povidone; hypromellose; sodium stearylfumarate; microcrystalline cellulose; sodium alginate; magnesium stearate; hyprolose; macrogol 400; macrogol 6000; purified talc; colloidal anhydrous silica; titanium dioxide; iron oxide red; iron oxide yellow; iron oxide black; docusate sodium - tarka is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 5 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; macrogol 6000; colloidal anhydrous silica; maltodextrin; magnesium stearate; colour - treatment of hypertension. treatment should not be initiated with this combination.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; hyprolose; magnesium stearate; isomalt; colloidal anhydrous silica; hypromellose; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril arginine, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; isomalt; magnesium stearate; hypromellose; brilliant blue fcf aluminium lake; titanium dioxide; hyprolose; colloidal anhydrous silica; macrogol 8000 - treatment of hypertension and the treatment of heart failure. in such patients it is recommended that perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.